Is it possible to make cross-study comparisons of urinary continence rates in patients with overactive bladder?

Abstract

Several antimuscarinic agents are available for the treatment of overactive bladder but there are few head-to-head studies to guide physicians in choosing one over another. Here we propose ways in which logical adjustments can be made to account for differences in disease seventy and placebo effects when considering continence data to allow estimation of relative effectiveness across studies. © 2005 Librapharm Limited.